OR WAIT 15 SECS
How does MBU plan to position the School of Paramedical & Allied Healthcare Sciences as a centre of excell...
India and the European Union (EU) have announced the conclusion of negotiations for a Free Trade Agreement (FT...
Avio Smart Market Stack (ASMS) (formerly Bartronics India Limited) has signed a Share Subscription cum Sh...
Can India’s CDMOs Lead the Next Biopharma Wave?
India’s Contract, Development, and Manufacturing Organisation (CDMO) sector is projected to grow from $3–3.5 billion today to $22–25 billion by 2035, noted Boston Consulting Group (BCG). While small molecules continue to form the backbone of manufacturing, new opportunities are emerging in biologics, antibody drug conjugates (ADCs), gene therapies, and RNA therapeutics. As India gears up for this next phase of expansion, what challenges stand in the way, and how is the industry preparing to address them? Let’s find out.
For Feedback, please email us at: communications@mmactiv.com
Sign up here to access BioSpectrum India Flip Book.
Sign up here to access BioSpectrum India Flip Book
